Stephen Davis - Oct 15, 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
CEO, Director
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Oct 15, 2022
Transactions value $
-$44,331
Form type
4
Date filed
10/18/2022, 09:16 PM
Previous filing
Sep 2, 2022
Next filing
Dec 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +5.94K +7.83% 81.8K Oct 15, 2022 Direct F1
transaction ACAD Common Stock Sale -$44.3K -2.8K -3.43% $15.81 79K Oct 15, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -5.94K -100% $0.00* 0 Oct 15, 2022 Common Stock 5.94K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3 The restricted stock units vest in four equal annual installments beginning 10/15/19.